不可手术非小细胞肺癌常规分割与大分割加速放疗的长期生活质量:CHARTWEL随机试验结果
该研究分析CHARTWEL III期试验中最大单中心亚组160例不可手术非小细胞肺癌患者,比较常规分割放疗(CF)与连续超分割加速放疗(CHARTWEL)的生活质量(QoL)。三年内CHARTWEL组在疲乏、疼痛、呼吸困难方面优于CF,全球QoL及吞咽困难无显著差异。
要点
- CHARTWEL组三年内疲乏、疼痛、呼吸困难评分优于CF组。
- 全球QoL与吞咽困难在两组间无显著差异。
- 12个月时CHARTWEL组无病且QoL良好或存活概率较高。
核心结论
- 三年内CHARTWEL组生活质量相似或优于CF组。
- QoL与疾病状态联合建模可提供额外治疗比较信息。
研究设计与样本
- 分析CHARTWEL III期随机试验中最大单中心亚组,随访至随机化后三年。
- 共160例(98%)患者提供至少一次QoL评估,使用QLQ-C30和QLQ-LC13问卷,线性混合模型比较。
主要发现
- CF vs CHARTWEL三年平均治疗差异:全球QoL -5.4分(95%CI [-13.6,2.8],p=0.19),疲乏11.9分([2.8,21.0],p=0.01),疼痛13.4分([3.5,23.3],p=0.009),呼吸困难10.5分([1.3,19.6],p=0.03),吞咽困难5.2分([-2.7,13.0],p=0.19)。
- 12个月时CF组无病且QoL良好、良好或中等、任意全球QoL、存活概率分别为5.1%、20.3%、34.2%、54.4%;CHARTWEL组分别为10.4%、21.0%、37.5%、65.3%。
临床怎么用
- 对于不可手术非小细胞肺癌,CHARTWEL方案在疲乏、疼痛、呼吸困难方面可能带来更优的长期生活质量。
局限性
- 分析仅基于最大单中心亚组,非全试验人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the quality of life (QoL) of patients with inoperable non-small cell lung cancer treated with conventionally fractionated radiotherapy (CF) vs. continuous hyperfractionated accelerated radiotherapy weekend-less (CHARTWEL). MATERIAL AND METHODS: The largest monocentric subgroup of the phase III CHARTWEL trial was analyzed up to three years after randomization. QoL was assessed with the European Organization for Research and Treatment of Cancer QoL Core Questionnaire (QLQ-C30) and lung cancer module (QLQ-LC13) and compared using linear mixed models. QoL interrelations with recurrence, metastasis, and death were explored by multi-state modeling. RESULTS: 160 patients (98%) provided at least one QoL assessment. Average treatment differences of CF vs. CHARTWEL over three years were -5.4 points (95%CI [-13.6,2.8], p = 0.19) in global QoL, 11.9 ([2.8,21.0], p = 0.01) in fatigue, 13.4 ([3.5,23.3], p = 0.009) in pain, 10.5 ([1.3,19.6], p = 0.03) in dyspnea, and 5.2 ([-2.7,13.0], p = 0.19) in dysphagia. At 12 months, the probabilities of being disease-free with good, good or moderate, any global QoL, or alive were 5.1%, 20.3%, 34.2%, 54.4% under CF and 10.4%, 21.0%, 37.5%, 65.3% under CHARTWEL. CONCLUSIONS: Over three years, QoL was similar or more favorable under CHARTWEL compared to CF. Modeling QoL together with disease states provided additional insight into treatment comparisons.
引用
- Hechtner M, Krause M, König J, et al. Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy - Results of the randomized CHARTWEL trial. Radiother Oncol. 2017. PMID: 29273262. doi:10.1016/j.radonc.2017.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。